Novel computational approaches to polypharmacology as a means to define responses to individual drugs.
暂无分享,去创建一个
[1] Eyke Hüllermeier,et al. SEGA: Semiglobal Graph Alignment for Structure-Based Protein Comparison , 2011, IEEE/ACM Transactions on Computational Biology and Bioinformatics.
[2] C. Hirschhäuser,et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy , 2011, Nature Medicine.
[3] Lei Xie,et al. Structure-based systems biology for analyzing off-target binding. , 2011, Current opinion in structural biology.
[4] Philip E. Bourne,et al. Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir , 2011, PLoS Comput. Biol..
[5] John P. Overington,et al. Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.
[6] H Steven Wiley,et al. Integrating Multiple Types of Data for Signaling Research: Challenges and Opportunities , 2011, Science Signaling.
[7] Olga G. Troyanskaya,et al. Accurate Quantification of Functional Analogy among Close Homologs , 2011, PLoS Comput. Biol..
[8] Wei Liu,et al. A Mathematical Framework for Protein Structure Comparison , 2011, PLoS Comput. Biol..
[9] Ferran Sanz,et al. A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity , 2011, J. Chem. Inf. Model..
[10] Jason Weston,et al. Detecting Remote Evolutionary Relationships among Proteins by Large-Scale Semantic Embedding , 2011, PLoS Comput. Biol..
[11] J. Skolnick,et al. Structural space of protein–protein interfaces is degenerate, close to complete, and highly connected , 2010, Proceedings of the National Academy of Sciences.
[12] Douglas A Lauffenburger,et al. A mammalian functional-genetic approach to characterizing cancer therapeutics. , 2010, Nature chemical biology.
[13] Yang Li,et al. Critical reasoning on causal inference in genome-wide linkage and association studies. , 2010, Trends in genetics : TIG.
[14] Kevin Y. Yip,et al. Extensive In Vivo Metabolite-Protein Interactions Revealed by Large-Scale Systematic Analyses , 2010, Cell.
[15] Philip E. Bourne,et al. PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..
[16] Karsten Zengler,et al. The challenges of integrating multi-omic data sets. , 2010, Nature chemical biology.
[17] Philip E. Bourne,et al. The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications , 2010, PLoS Comput. Biol..
[18] Tudor I. Oprea,et al. ChemProt: a disease chemical biology database , 2010, Nucleic Acids Res..
[19] Dan S. Tawfik. Messy biology and the origins of evolutionary innovations. , 2010, Nature chemical biology.
[20] Jeffrey Skolnick,et al. iAlign: a method for the structural comparison of protein-protein interfaces , 2010, Bioinform..
[21] Peer Bork,et al. Drug-Induced Regulation of Target Expression , 2010, PLoS Comput. Biol..
[22] Philip E. Bourne,et al. Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..
[23] A. Armaou,et al. Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action. , 2010, Journal of theoretical biology.
[24] R. Tagliaferri,et al. Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.
[25] Stéphanie Pérot,et al. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. , 2010, Drug discovery today.
[26] Barry Honig,et al. VASP: A Volumetric Analysis of Surface Properties Yields Insights into Protein-Ligand Binding Specificity , 2010, PLoS Comput. Biol..
[27] P. Tonge,et al. Drug-target residence time: critical information for lead optimization. , 2010, Current opinion in chemical biology.
[28] Andreas Schmid,et al. Systems biology: Hypothesis-driven omics integration. , 2010, Nature chemical biology.
[29] W. Hahn,et al. On or Off Target: Mutations, Models, and Predictions , 2010, Science Translational Medicine.
[30] Raquel Norel,et al. Protein interface conservation across structure space , 2010, Proceedings of the National Academy of Sciences.
[31] Bin Chen,et al. Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data , 2010, BMC Bioinformatics.
[32] Gisbert Schneider,et al. Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.
[33] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[34] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[35] K. Chou,et al. Predicting Drug-Target Interaction Networks Based on Functional Groups and Biological Features , 2010, PloS one.
[36] Jean-Philippe Vert,et al. A new protein binding pocket similarity measure based on comparison of clouds of atoms in 3D: application to ligand prediction , 2010, BMC bioinformatics.
[37] Pedro J Ballester,et al. Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases , 2010, Journal of The Royal Society Interface.
[38] Joel Dudley,et al. Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..
[39] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[40] J. Fletcher,et al. ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.
[41] Valerie A. Braz,et al. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers. , 2010, Biochemistry.
[42] Jie Wu,et al. BSSF: a fingerprint based ultrafast binding site similarity search and function analysis server , 2010, BMC Bioinformatics.
[43] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[44] Owen J. Sansom,et al. Genetic Dissection of Differential Signaling Threshold Requirements for the Wnt/β-Catenin Pathway In Vivo , 2010, PLoS genetics.
[45] J. C. Pastor-Pareja,et al. Interaction between RasV12 and scribble clones induces tumour growth and invasion , 2009, Nature.
[46] James E Ferrell,et al. Signaling motifs and Weber's law. , 2009, Molecular cell.
[47] M. Cyert,et al. Cracking the Phosphatase Code: Docking Interactions Determine Substrate Specificity , 2009, Science Signaling.
[48] Damian Szklarczyk,et al. STITCH 2: an interaction network database for small molecules and proteins , 2009, Nucleic Acids Res..
[49] A. Fliri,et al. Drug effects viewed from a signal transduction network perspective. , 2009, Journal of medicinal chemistry.
[50] Aleksandar Poleksic,et al. Algorithms for optimal protein structure alignment , 2009, Bioinform..
[51] Ruili Huang,et al. Comprehensive Characterization of Cytochrome P450 Isozyme Selectivity across Chemical Libraries , 2009, Nature Biotechnology.
[52] Dana Pe'er,et al. Harnessing gene expression to identify the genetic basis of drug resistance , 2009, Molecular systems biology.
[53] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[54] J. Mestres,et al. Conciliating binding efficiency and polypharmacology. , 2009, Trends in pharmacological sciences.
[55] Bin Chen,et al. PubChem as a Source of Polypharmacology , 2009, J. Chem. Inf. Model..
[56] Najeeb M. Halabi,et al. Protein Sectors: Evolutionary Units of Three-Dimensional Structure , 2009, Cell.
[57] Michael Nilges,et al. Shelling the Voronoi interface of protein–protein complexes reveals patterns of residue conservation, dynamics, and composition , 2009, Proteins.
[58] Guanghui Hu,et al. Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.
[59] Daniel E. Newburger,et al. Diversity and Complexity in DNA Recognition by Transcription Factors , 2009, Science.
[60] Yanli Wang,et al. PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..
[61] Hiroki Kobayashi,et al. Integrating Statistical Predictions and Experimental Verifications for Enhancing Protein-Chemical Interaction Predictions in Virtual Screening , 2009, PLoS Comput. Biol..
[62] Eric K. Neumann,et al. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships , 2009, BMC Bioinformatics.
[63] Philip E. Bourne,et al. Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors , 2009, PLoS Comput. Biol..
[64] J. Ferrell,et al. Tuning the Activation Threshold of a Kinase Network by Nested Feedback Loops , 2009, Science.
[65] P. Sorger,et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.
[66] Eugenio Uriarte,et al. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. , 2009, Molecular pharmaceutics.
[67] Paul W Finn,et al. Ultrafast shape recognition: evaluating a new ligand-based virtual screening technology. , 2009, Journal of molecular graphics & modelling.
[68] P. Tonge,et al. Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. , 2009, ACS chemical biology.
[69] Lei Wu,et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. , 2009, Microvascular research.
[70] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[71] R. Fässler,et al. Genetic and cell biological analysis of integrin outside-in signaling. , 2009, Genes & development.
[72] Diego di Bernardo,et al. Identifying Network of Drug Mode of Action by Gene Expression Profiling , 2009, J. Comput. Biol..
[73] Angelo D. Favia,et al. Protein promiscuity and its implications for biotechnology , 2009, Nature Biotechnology.
[74] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[75] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[76] K. Shokat,et al. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.
[77] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[78] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[79] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[80] Didier Rognan,et al. How to Measure the Similarity Between Protein Ligand-Binding Sites? , 2008 .
[81] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[82] Yoshihiro Yamanishi,et al. Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.
[83] A. Singleton,et al. Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.
[84] Emma Griffiths,et al. Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr , 2008, Proceedings of the National Academy of Sciences.
[85] Jacob D. Feala,et al. Search Algorithms as a Framework for the Optimization of Drug Combinations , 2008, PLoS Comput. Biol..
[86] E. Segal,et al. Predicting expression patterns from regulatory sequence in Drosophila segmentation , 2008, Nature.
[87] David S. Wishart,et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..
[88] Robert B. Russell,et al. SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..
[89] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[90] R. Lange,et al. The targets of currently used antibacterial agents: lessons for drug discovery. , 2007, Current pharmaceutical design.
[91] P. Clemons,et al. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. , 2007, Combinatorial chemistry & high throughput screening.
[92] Liang Shen,et al. Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery , 2007, Genome Biology.
[93] István A. Kovács,et al. How to design multi-target drugs , 2007, Expert opinion on drug discovery.
[94] David J. Mooney,et al. Microenvironmental regulation of biomacromolecular therapies , 2007, Nature Reviews Drug Discovery.
[95] Ronald Koschny,et al. The promise of TRAIL—potential and risks of a novel anticancer therapy , 2007, Journal of Molecular Medicine.
[96] H. Kitano. A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.
[97] Richard Morphy,et al. Fragments, network biology and designing multiple ligands. , 2007, Drug discovery today.
[98] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[99] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[100] Bruce N. Ames,et al. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage , 2006, Proceedings of the National Academy of Sciences.
[101] Philip E. Bourne,et al. Modern proteomes contain putative imprints of ancient shifts in trace metal geochemistry , 2006, Proceedings of the National Academy of Sciences.
[102] Marc S. Cortese,et al. Rational drug design via intrinsically disordered protein. , 2006, Trends in biotechnology.
[103] T. Golub,et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.
[104] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[105] R. Weinshilboum,et al. Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.
[106] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2006, Nature Reviews Drug Discovery.
[107] L. Piddock. Multidrug-resistance efflux pumps ? not just for resistance , 2006, Nature Reviews Microbiology.
[108] J C Reed,et al. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins , 2006, Cell Death and Differentiation.
[109] Amos Tanay,et al. Extensive low-affinity transcriptional interactions in the yeast genome. , 2006, Genome research.
[110] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[111] Meir Glick,et al. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..
[112] B. Palsson,et al. The model organism as a system: integrating 'omics' data sets , 2006, Nature Reviews Molecular Cell Biology.
[113] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[114] P. Ridker,et al. Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.
[115] Joseph Loscalzo,et al. Cyclooxygenase inhibition and cardiovascular risk. , 2005, Circulation.
[116] T. Klabunde,et al. GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.
[117] J. A. Grant,et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.
[118] J. Jenkins,et al. A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. , 2004, Journal of medicinal chemistry.
[119] S. Pongor,et al. Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.
[120] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[121] P. Csermely. Strong links are important, but weak links stabilize them. , 2004, Trends in biochemical sciences.
[122] S. Lipton. Turning down, but not off , 2004, Nature.
[123] J. Whisstock,et al. Prediction of protein function from protein sequence and structure , 2003, Quarterly Reviews of Biophysics.
[124] Tony Pawson,et al. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication , 2001, Nature.
[125] F. Cohen,et al. Co-evolution of proteins with their interaction partners. , 2000, Journal of molecular biology.
[126] Ajay N. Jain. Morphological similarity: A 3D molecular similarity method correlated with protein-ligand recognition , 2000, J. Comput. Aided Mol. Des..
[127] Yvonne C. Martin,et al. Use of Structure-Activity Data To Compare Structure-Based Clustering Methods and Descriptors for Use in Compound Selection , 1996, J. Chem. Inf. Comput. Sci..
[128] K. Lewis,et al. Multidrug resistance pumps in bacteria: variations on a theme. , 1994, Trends in biochemical sciences.
[129] Qing Yan. Membrane transporters and drug development: relevance to pharmacogenomics, nutrigenomics, epigenetics, and systems biology. , 2010, Methods in molecular biology.
[130] P Schneider,et al. Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. , 2009, Current medicinal chemistry.
[131] D. Kell,et al. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. , 2009, Drug discovery today.
[132] Alexandre Varnek,et al. Chemoinformatics approaches to virtual screening , 2008 .
[133] John A. Tallarico,et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.
[134] Justin Lamb,et al. The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.
[135] K. Yoshikawa,et al. Weak interaction induces an ON/OFF switch, whereas strong interaction causes gradual change: folding transition of a long duplex DNA chain by poly-L-lysine. , 2007, Biomacromolecules.
[136] Martin Serrano,et al. Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .
[137] Jerry J Buccafusco,et al. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.
[138] X. Chen,et al. TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..
[139] Joshua M. Stuart,et al. Integrating genotype and phenotype information: an overview of the PharmGKB project , 2001, The Pharmacogenomics Journal.
[140] Osman F. Güner,et al. Pharmacophore perception, development, and use in drug design , 2000 .